BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Deals

  Reckitt CEO’s $17B Predicament

  2018 is the year for Rakesh Kapoor to show he’s worth it.

  December 27, 2017

   · 

  1 min read
• LP Pharma of Xiamen Raises $30M for Drugs With Mucosa/Oral Delivery

  LP Pharma raised $30M in a B round led by state-owned SDIC Fund Management.

  December 27, 2017

   · 

  1 min read
• 

  Business

  Carefusion Snags Five-Year $50M Pentagon Contract

  The military reviewed bids from 31 suitors and is good to Dec. 20, 2022.

  December 27, 2017

   · 

  1 min read
• Business

  Week in Review: Nearly $2B Late-December Week for China Pharma Deals

  Nanjing Legend Biotech received a very large $350M upfront payment from Janssen Biotech to partner Legend’s impressively effective CAR-T candidate.

  December 27, 2017

   · 

  1 min read
• 

  BioCapital

  7 Weird Superstitions and Rituals of Scientists

  A look at some of the superstitions and rituals that scientists apply to their work.

  December 27, 2017

   · 

  6 min read

   · 

  Mark Terry
• 

  Drug Development

  Sarepta Shows Off Long-Term Pulmonary Function of Eteplirsen-Treated DMD Patients

  A statistically significant and clinically meaningful reduction in pulmonary decline was observed for the eteplirsen-treated patients.

  December 27, 2017

   · 

  6 min read
• Policy

  Eisai: Anticancer Agent Lenvatinib Designated for Priority Review and Approval by CFDA for Hepatocellular Carcinoma

  The Priority Review and Approval procedure was implemented by the CFDA in February 2016 with the aim of accelerating research, development and launch of new medicines that have significant clinical value.

  December 27, 2017

   · 

  4 min read
• Drug Development

  Innovation Pharmaceuticals Obtains Direct Evidence of Molecular Pathways Modulation in Tumors From First Patients in Kevetrin PhIIa Ovarian Cancer Trial

  The findings confirm in patient tumors Kevetrin-induced anti-cancer effects similar to those demonstrated (pdf) preclinically in ovarian cancer cell-lines.

  December 27, 2017

   · 

  9 min read
• Drug Development

  Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 Mutation

  Agios has requested priority review for the application, which, if granted, could result in a six-month review process.

  December 27, 2017

   · 

  5 min read
• Policy

  FDA Grants Orphan Drug Designation to Aptose Biosciences for CG’806 in Acute Myeloid Leukemia

  Orphan drug designation provides Aptose certain benefits, including market exclusivity upon regulatory approval if received, exemption of FDA application fees and tax credits for qualified clinical trials.

  December 27, 2017

   · 

  5 min read